Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.67 |
| ▸ | GAK | O14976 | 1/20 | 0.67 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.65 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.62 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29719131 | 1.00 | EGFR (0.67) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL2533904 | 0.92 | EGFR (0.70) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL16212746 | 0.92 | EGFR (0.69) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL29719074 | 0.92 | EGFR (0.69) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL2533768 | 0.89 | EGFR (0.79) | EGFRGAKERBB2ERBB4 | |
| SCHEMBL16212314 | 0.89 | EGFR (0.70) | EGFRGAKERBB2ERBB4 | |
| SCHEMBL15928200 | 0.88 | EGFR (0.67) | EGFRGAKERBB2ERBB4 | |
| SCHEMBL15928186 | 0.88 | EGFR (0.67) | EGFRGAKERBB2ERBB4 | |
| SCHEMBL22983689 | 0.86 | EGFR (0.64) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL233118 | 0.85 | EGFR (0.70) | EGFRGAKERBB2ERBB4ERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013749-B1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12435046-B2 | Alkynyl quinazoline compounds | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20220298120-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| CN-114787150-A | Alkynyl quinazoline compounds | 黑钻治疗公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-4013749-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | Black Diamond Therapeutics, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021030711-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435046-B2 | Alkynyl quinazoline compounds | GLS, GLS2, MCL1 | EGFR 677/4885GAK 612/4885ERBB2 691/4885 |
| US-20220298120-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | GLS, GLS2, MCL1 | EGFR 677/4885GAK 612/4885ERBB2 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.